Barak V - Search Results

1

Karlikova M, Topolcan O, Wolfe OT, Barak V, Zima T. Karlikova M, et al. Among authors: barak v. Biomed Res Int. 2015;2015:423159. doi: 10.1155/2015/423159. Epub 2015 Aug 4. Biomed Res Int. 2015. PMID: 26345426 Free PMC article. No abstract available.

2

Serum interleukin 1 beta levels as a marker in hairy cell leukemia: correlation with disease status and sIL-2R levels.

Barak V, Nisman B, Dann EJ, Kalickman I, Ruchlemer R, Bennett MA, Polliack A. Barak V, et al. Leuk Lymphoma. 1994;14 Suppl 1:33-9. Leuk Lymphoma. 1994. PMID: 7820051

3

Evaluation of tissue polypeptide specific antigen, CYFRA 21-1, and carcinoembryonic antigen in nonsmall cell lung carcinoma: does the combined use of cytokeratin markers give any additional information?

Nisman B, Lafair J, Heching N, Lyass O, Baras M, Peretz T, Barak V. Nisman B, et al. Among authors: barak v. Cancer. 1998 May 15;82(10):1850-9. doi: 10.1002/(sici)1097-0142(19980515)82:10<1850::aid-cncr6>3.0.co;2-r. Cancer. 1998. PMID: 9587116 Clinical Trial.

4

Cytokeratin markers in malignant pleural mesothelioma.

Nisman B, Barak V, Heching N, Kramer M, Reinus C, Lafair J. Nisman B, et al. Among authors: barak v. Cancer Detect Prev. 1998;22(5):416-21. doi: 10.1046/j.1525-1500.1998.00053.x. Cancer Detect Prev. 1998. PMID: 9727622

5

The tumor necrosis factor family and and correlation with disease activity and response to treatment in hairy cell leukemia.

Barak V, Nisman B, Polliack A. Barak V, et al. Eur J Haematol. 1999 Feb;62(2):71-5. doi: 10.1111/j.1600-0609.1999.tb01724.x. Eur J Haematol. 1999. PMID: 10052708

6

Serum markers to detect metastatic uveal melanoma.

Barak V, Frenkel S, Kalickman I, Maniotis AJ, Folberg R, Pe'er J. Barak V, et al. Anticancer Res. 2007 Jul-Aug;27(4A):1897-900. Anticancer Res. 2007. PMID: 17649791 Free PMC article.

7

Using the direct-injection model of early uveal melanoma hepatic metastasis to identify TPS as a potentially useful serum biomarker.

Barak V, Frenkel S, Valyi-Nagy K, Leach L, Apushkin MA, Lin AY, Kalickman I, Baumann NA, Pe'er J, Maniotis AJ, Folberg R. Barak V, et al. Invest Ophthalmol Vis Sci. 2007 Oct;48(10):4399-402. doi: 10.1167/iovs.07-0552. Invest Ophthalmol Vis Sci. 2007. PMID: 17898257

8

The follow-up of patients with non-muscle-invasive bladder cancer by urine cytology, abdominal ultrasound and urine CYFRA 21-1: a pilot study.

Nisman B, Yutkin V, Peretz T, Shapiro A, Barak V, Pode D. Nisman B, et al. Among authors: barak v. Anticancer Res. 2009 Oct;29(10):4281-5. Anticancer Res. 2009. PMID: 19846987 Free article. Clinical Trial.

9

The diagnostic and prognostic value of ProGRP in lung cancer.

Nisman B, Biran H, Ramu N, Heching N, Barak V, Peretz T. Nisman B, et al. Among authors: barak v. Anticancer Res. 2009 Nov;29(11):4827-32. Anticancer Res. 2009. PMID: 20032442 Free article.

10

Relevance of circulating biomarkers for the therapy monitoring and follow-up investigations in patients with non-small cell lung cancer.

Barak V, Holdenrieder S, Nisman B, Stieber P. Barak V, et al. Cancer Biomark. 2010;6(3-4):191-6. doi: 10.3233/CBM-2009-0129. Cancer Biomark. 2010. PMID: 20660964 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

216 results

Search Page